Ensuring Compliance with Advertising and Promotional Requirements for Drugs and Medical Devices (Chicago, IL - July 26-27, 2018)

  • ID: 4515276
  • Conference
  • Location: Chicago, IL
  • 2 Days
  • Compliance Online
  • Conference Dates: July 26-27, 2018
1 of 5

Federal regulation of the advertising and promotion of pharmaceuticals and medical devices reflects an aggressive attitude on the part of the regulators that demands, in turn, that industry be keenly aware of the legal and regulatory duties, as well as key recent trends in enforcement activities by the Federal Government. This course will explore in detail what FDA requires of drug and device firms as well as recent current hot buttons in FDA enforcement activity for the advertising arena.

What’s at stake if your advertising and promotional efforts violate the law? Colossal fines – the latest was $3 Billion; criminal liability, including even prison time; and huge disruption in operations while dealing with federal probes into illegal marketing.

Seminar Fee Includes:

  • Lunch
  • AM-PM Tea/Coffee
  • Seminar Material
  • USB with seminar presentation
  • Hard copy of presentation
  • Attendance Certificate
  • $100 Gift Cert for next seminar
  • Download Brochure

Learning Objectives:

Key goals of the conference will include learning:

  • The basics of FDA law and regulations governing advertising and promotion, as well as sister agencies such as the Federal Trade Commission, which shares jurisdiction with FDA on certain regulated products (e.g., OTC drugs).
  • The distinctions between labels, labeling and advertising and how that impacts FDA's powers, and
  • How to properly position Direct-to-Consumer (DTC) promotions
  • The Dos and Don'ts of promoting products on the internet, including social media sites such as Facebook and Twitter
  • The perils of off-label promotion, including criminal and civil actions that have led to multi-billion dollar settlements by regulated drug companies
  • Whether the First Amendment provides any insulation for truthful statements regarding regulated products;
  • When disseminating medical educational materials crosses the line into improper promotion; and
  • Key considerations on how to implement appropriate procedures and controls in your company to minimize the potential for regulatory action by the FDA or the FTC relative to promotion and advertising.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

DAY ONE (8:30 AM – 4:30 PM)
Registration Process: 8:30 AM – 9:00 AM

Session Start Time: 9:00 AM

I. Understanding the Basics
 Who Has Jurisdiction
 Drugs & Biologics
 Rx Drug Advertising
 OTC Drug Advertising
 Devices
 Restricted
 all other Labeling vs. Advertising
 Basic drug rules
 Fair balance
 Device rules
 Intended use deviations
 DTC advertising
 Print
 TV
 Comparative Claims standard to support
 push to pursue CER
 Detailing and Sampling
 is there still a future?
 what can be said?
 danger of “custom” pieces
 How FDA learns of violations
 Keep your house clean or your competitors will rat you out

II. Scientific Exchange
 Guidances on Dissemination of Scientific Information
 Risks involved in OffLabel Statements
 Procedural Requirements and Unsolicited Requests for Information

III. First Amendment
 Understanding “Commercial Speech” Doctrine
 FDA and the Regulation of Advertising

IV. Websites & Social Media
 FDA Policies on the Internet
 Recent FDA Enforcement Activities
 How to Handle at the Company Levels

DAY TWO (8:30 AM – 4:30 PM)

V. Enforcement Trends
 FDA Hot Buttons
 Understating risk
 Overstating effectiveness
 FTC
 POM Wonderful and substantiation
 Private Litigation – Understanding
 Lanham Act
 State Unfair Competition

VI. False Claims Act and Criminal Liability
 Review of Key Settlements
 “Responsible Corporate Official” Liability

VII. Handling at the Company Level
 Compliance Programs
 Internal processes

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Michael A Swit, Esq. Mr Michael A Swit, Esq.,
    FDA Lawyer ,
    U.S. Food & Drug Administration


    Michael A. Swit focuses on solving the legal challenges confronted by the pharmaceutical, medical device, and other life sciences industries in tackling the myriad of legal mandates enforced by the U.S. Food & Drug Administration. Mr. Swit has extensive experience counseling life sciences firms on the demands of compliance with FDA's statutory and regulatory requirements to develop and market safe and effective drugs, biologics, medical devices, IVDs and other products. He also has advised regulated firms on a wide range of FDA regulatory matters, including drug and device approvals and marketing/promotional claims, dietary supplement health claims and regulatory issues in corporate acquisitions. His experience includes FDA development strategies, compliance and enforcement initiatives, recalls and crisis management, submissions and related traditional FDA regulatory activities, labeling and advertising, and clinical research efforts.

    Mr. Swit has been addressing critical FDA legal and regulatory issues since 1984. Before joining Duane Morris LLP, Mr. Swit served for seven years as vice president at a preeminent scientific and FDA regulatory consulting firm, where he developed and ensured execution of a broad array of regulatory and other services to clients, both directly and through outside counsel.

    His multi-faceted experience includes serving for three and a half years as corporate vice president, general counsel and secretary of Par Pharmaceutical, a prominent, publicly-traded, generic drug company and, thus, he brings an industry and commercial perspective to his work with FDA-regulated companies. While at Par, he spearheaded Par's successful response to multiple federal and state criminal and civil investigations arising out of the actions of prior management. Mr. Swit then served for over four years as CEO of FDAnews.com, a premier publisher of FDA regulatory newsletters and other specialty information products for the FDA-regulated community. His private FDA regulatory law practice also has included service as counsel in the FDA practices of three international law firms, as well as a solo FDA practitioner.

    Mr. Swit has taught and written on a wide variety of subjects relating to FDA law, regulation and related commercial activities, including, since 1989, co-directing a three-day intensive course on the generic drug approval process and editing a guide to the generic drug approval process, Getting Your Generic Drug Approved. A former member of the Food & Drug Law Journal Editorial Board, Mr. Swit also has been a prominent speaker at numerous conferences sponsored by such organizations as the Food & Drug Law Institute (FDLI), the Regulatory Affairs Professionals Society (RAPS), and the Drug Information Association (DIA).

    Mr. Swit is a 1982 graduate of Emory School of Law and a magna cum laude graduate of Bowdoin College (1979), with high honors in history

Note: Product cover images may vary from those shown
5 of 5

Who will Benefit:

Senior executives, directors, managers and those who have responsibility for implementing advertising and promotional activities, as well as those that have key collateral roles in reviewing advertising for drug and device firms, including officials from these areas within regulated companies:

  • Sales
  • Marketing
  • Medical Affairs
  • Legal
  • Regulatory
  • Compliance
Note: Product cover images may vary from those shown
6 of 5

ADDRESS

Chicago, IL

Venue to be announced shortly.

Note: Product cover images may vary from those shown
Adroll
adroll